Elsayed Mohamed Mamdouh, Elkazaz Amr Mohamed
Nephrology and Internal Medicine Department, Faculty of Medicine, Alexandria University, Alkhartoom Square, El Azareeta, Alexandria, 21131, Egypt.
Internal Medicine Department, El Qabbary General Hospital, Ministry of Health, Alexandria, Egypt.
Clin Exp Nephrol. 2025 May;29(5):672-680. doi: 10.1007/s10157-025-02626-7. Epub 2025 Jan 18.
Oral nutritional supplements (ONS) are commonly prescribed to provide protein and energy to hemodialysis (HD) patients. There is a debate about the appropriate timing to administer ONS. We aimed to study the effect of different timings of ONS on variable outcomes in HD patients.
This research is a prospective, randomized, multicentric clinical trial (RCT) that included 120 patients on regular HD. Patients were allocated to receive ONS (25 gm protein powder/HD session) for 8 weeks either predialytic (1 h before the start of the session), intradialytic (2 h after the start of the session), or interdialytic (on non-dialysis days). Laboratory parameters, blood pressure (BP), dialysis adequacy, and nutritional parameters were assessed during the study.
At study end, BP at the end of HD dropped significantly in the intradialytic group compared to the other groups (p < 0.001). Serum albumin improved significantly in the predialytic (p < 0.001) and intradialytic (p = 0.039) groups. The mean subjective global assessment score increased significantly in the interdialytic group (p = 0.040). The Kt/V and urea reduction ratio decreased significantly only in the intradialytic group (p value < 0.001 and 0.001). Serum sodium, potassium, phosphorus, cholesterol, triglycerides, and adverse events did not significantly differ between the different groups.
Predialytic ONS supplementation is a favorable option due to improved serum albumin with minimal effects on hemodynamics and dialysis adequacy compared to intradialytic and interdialytic supplementation.
ClinicalTrials.gov NCT05953636. First registration date: 1/07/2023.
口服营养补充剂(ONS)通常用于为血液透析(HD)患者提供蛋白质和能量。关于ONS给药的合适时间存在争议。我们旨在研究不同时间给予ONS对HD患者不同结局的影响。
本研究是一项前瞻性、随机、多中心临床试验(RCT),纳入120例规律HD患者。患者被分配接受ONS(每次HD治疗25克蛋白粉),持续8周,分别在透析前(治疗开始前1小时)、透析中(治疗开始后2小时)或透析间期(非透析日)服用。研究期间评估实验室参数、血压(BP)、透析充分性和营养参数。
研究结束时,与其他组相比,透析中组HD结束时的BP显著下降(p<0.001)。透析前组(p<0.001)和透析中组(p=0.039)的血清白蛋白显著改善。透析间期组的平均主观全面评定评分显著增加(p=0.040)。仅透析中组的Kt/V和尿素清除率显著下降(p值<0.001和0.001)。不同组之间的血清钠、钾、磷、胆固醇、甘油三酯和不良事件无显著差异。
与透析中和透析间期补充相比,透析前补充ONS是一个较好的选择,因为它能改善血清白蛋白,对血流动力学和透析充分性的影响最小。
ClinicalTrials.gov NCT05953636。首次注册日期:2023年7月1日。